Should I buy or sell Foghorn Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Foghorn Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" FHTX shares. View FHTX analyst ratings or view top-rated stocks .

What is Foghorn Therapeutics' stock price target for 2024?

3 Wall Street research analysts have issued 12 month price targets for Foghorn Therapeutics' shares. Their FHTX share price targets range from $6.00 to $20.00. On average, they expect the company's stock price to reach $15.40 in the next year. This suggests a possible upside of 166.4% from the stock's current price. View analysts price targets for FHTX or view top-rated stocks among Wall Street analysts .

How have FHTX shares performed in 2024?

Foghorn Therapeutics' stock was trading at $6.45 on January 1st, 2024. Since then, FHTX shares have decreased by 10.4% and is now trading at $5.78. View the best growth stocks for 2024 here .

When is Foghorn Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our FHTX earnings forecast .

How were Foghorn Therapeutics' earnings last quarter?

Foghorn Therapeutics Inc. (NASDAQ:FHTX) issued its quarterly earnings results on Thursday, March, 7th. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.22. The firm earned $5.77 million during the quarter, compared to the consensus estimate of $4.91 million.

What ETF holds Foghorn Therapeutics' stock?

Range Cancer Therapeutics ETF holds 14,641 shares of FHTX stock, representing 1.36% of its portfolio.

When did Foghorn Therapeutics IPO?

Foghorn Therapeutics (FHTX) raised $120 million in an initial public offering on Friday, October 23rd 2020. The company issued 7,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, Morgan Stanley and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

How do I buy shares of Foghorn Therapeutics?

Shares of FHTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:FHTX

Foghorn Therapeutics (FHTX) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free FHTX Stock Alerts

$5.78

-0.25 (-4.15%)

(As of 04/17/2024 ET)

Compare

Today's Range: $5.75
▼
$6.74
50-Day Range: $4.85
▼
$8.00
52-Week Range: $2.70
▼
$9.97

Volume: 135,861 shs
Average Volume: 153,817 shs
Market Capitalization: $246.03 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.40

Get Foghorn Therapeutics alerts:

Foghorn Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 166.4% Upside
$15.40 Price Target
Short Interest: Bearish
6.43% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.16
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.05) to ($1.61) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.86 out of 5 stars

Medical Sector

590th out of 913 stocks

Pharmaceutical Preparations Industry

251st out of 396 stocks

3.3

Analyst's Opinion

Consensus Rating
Foghorn Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Foghorn Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
6.43% of the float of Foghorn Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Foghorn Therapeutics has a short interest ratio ("days to cover") of 7.4.
Change versus previous month
Short interest in Foghorn Therapeutics has recently decreased by 4.80%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Foghorn Therapeutics does not currently pay a dividend.
Dividend Growth
Foghorn Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for FHTX.

2.9

News and Social Media Coverage

News Sentiment
Foghorn Therapeutics has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Foghorn Therapeutics this week, compared to 1 article on an average week.
Search Interest
4 people have searched for FHTX on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
MarketBeat Follows
3 people have added Foghorn Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Foghorn Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.23% of the stock of Foghorn Therapeutics is held by insiders.
Percentage Held by Institutions
61.55% of the stock of Foghorn Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Foghorn Therapeutics are expected to grow in the coming year, from ($2.05) to ($1.61) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Foghorn Therapeutics is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Foghorn Therapeutics is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Foghorn Therapeutics Stock (NASDAQ:FHTX)

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

FHTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

FHTX Stock News Headlines

April 16, 2024 | marketwatch.com

Foghorn Therapeutics Taps Kristian Humer as Finance Chief

April 16, 2024 | globenewswire.com

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer

April 18, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 12, 2024 | americanbankingnews.com

Foghorn Therapeutics (NASDAQ:FHTX) Stock Rating Reaffirmed by HC Wainwright

April 11, 2024 | americanbankingnews.com

Foghorn Therapeutics (NASDAQ:FHTX) Receives Outperform Rating from Wedbush

April 10, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Generation Bio (GBIO), Poseida Therapeutics (PSTX)

April 10, 2024 | markets.businessinsider.com

Foghorn Therapeutics: Buy Rating Affirmed Amidst Promising Pipeline and Strategic Alliances

April 9, 2024 | globenewswire.com

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

April 18, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 9, 2024 | finance.yahoo.com

Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans

April 8, 2024 | americanbankingnews.com

Foghorn Therapeutics (FHTX) to Release Quarterly Earnings on Tuesday

April 5, 2024 | finance.yahoo.com

Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference

April 5, 2024 | globenewswire.com

Foghorn Therapeutics to Participate in Needham's 23rd Annual Virtual Healthcare Conference

April 4, 2024 | finance.yahoo.com

Fed commentary, jobless claims data: What to Watch

March 26, 2024 | globenewswire.com

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

March 8, 2024 | bizjournals.com

Cambridge biotech discloses it quietly laid off 28% of its staff last year

March 7, 2024 | investorplace.com

FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q4 2023

March 7, 2024 | benzinga.com

Foghorn Therapeutics: Q4 Earnings Insights

March 7, 2024 | finanznachrichten.de

Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

March 7, 2024 | globenewswire.com

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

March 5, 2024 | globenewswire.com

Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909

February 28, 2024 | finance.yahoo.com

Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference

February 28, 2024 | globenewswire.com

Foghorn Therapeutics to Participate in Cowen's 44th Annual Health Care Conference

February 26, 2024 | thestreet.com

Foghorn Therapeutics Inc.

February 15, 2024 | investing.com

Foghorn Therapeutics Inc (FHTX)

February 12, 2024 | finance.yahoo.com

Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?

February 9, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Foghorn Therapeutics (FHTX), Sensus Healthcare (SRTS)

See More Headlines

Receive FHTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Foghorn Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:FHTX
CUSIP: N/A
CIK: 1822462
Web: foghorntx.com
Phone: 617-586-3100
Fax: N/A
Employees: 116
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.40
High Stock Price Target: $20.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +166.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-98,430,000.00
Net Margins: -288.17%
Pretax Margin: -275.80%
Return on Equity: N/A
Return on Assets: -30.01%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.11
Quick Ratio: 4.11

Sales & Book Value

Annual Sales: $34.16 million
Price / Sales: 7.20
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.83) per share
Price / Book: -3.16

Miscellaneous

Outstanding Shares: 42,566,000
Free Float: 38,637,000
Market Cap: $246.03 million
Optionable: Optionable
Beta: 3.13

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Adrian H. B. Gottschalk (Age 48)
President, CEO & Director
Comp: $784.65k
Dr. Steven F. Bellon Ph.D. (Age 59)
Chief Scientific Officer
Comp: $572.6k
Dr. Alfonso Quintas Cardama M.D. (Age 52)
Chief Medical Officer
Comp: $300.16k
Dr. Gerald R. Crabtree M.d.
Founder & Member of Scientific Advisory Board
Mr. Stephen J. DiPalma (Age 65)
Treasurer & Interim CFO
Ms. Karin Hellsvik
VP, Corporate Affairs & Investor Relations
Mr. Michael J. LaCascia (Age 59)
Chief Legal Officer
Comp: $565.5k
Mr. Saurabh Sewak Ph.D.
Vice President of Corporate Development
Mr. Carlos Costa (Age 50)
Chief People Officer
Ms. Fanny Cavalie (Age 46)
Chief Strategy & Business Operations Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FHTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Foghorn Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Foghorn Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" FHTX shares.
View FHTX analyst ratings or view top-rated stocks.
What is Foghorn Therapeutics' stock price target for 2024?: 3 Wall Street research analysts have issued 12 month price targets for Foghorn Therapeutics' shares. Their FHTX share price targets range from $6.00 to $20.00. On average, they expect the company's stock price to reach $15.40 in the next year. This suggests a possible upside of 166.4% from the stock's current price.
View analysts price targets for FHTX or view top-rated stocks among Wall Street analysts.
How have FHTX shares performed in 2024?: Foghorn Therapeutics' stock was trading at $6.45 on January 1st, 2024. Since then, FHTX shares have decreased by 10.4% and is now trading at $5.78.
View the best growth stocks for 2024 here.
When is Foghorn Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our FHTX earnings forecast.

How were Foghorn Therapeutics' earnings last quarter?: Foghorn Therapeutics Inc. (NASDAQ:FHTX) issued its quarterly earnings results on Thursday, March, 7th. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.22. The firm earned $5.77 million during the quarter, compared to the consensus estimate of $4.91 million.
What ETF holds Foghorn Therapeutics' stock?: Range Cancer Therapeutics ETF holds 14,641 shares of FHTX stock, representing 1.36% of its portfolio.
When did Foghorn Therapeutics IPO?: Foghorn Therapeutics (FHTX) raised $120 million in an initial public offering on Friday, October 23rd 2020. The company issued 7,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, Morgan Stanley and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
How do I buy shares of Foghorn Therapeutics?: Shares of FHTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FHTX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Foghorn Therapeutics (FHTX) Stock Price, News & Analysis

Foghorn Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Foghorn Therapeutics Stock (NASDAQ:FHTX)

FHTX Stock Price History

FHTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

FHTX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™